Antidepressant use with Hepatitis C?

Which of the following antidepressant have Level 1 evidence for treating depression during Hepatitis C treatment?

Before Scrolling Down ==>

Submit Your Answer First 🙂

According to this review article published in BMC Gastroenterology: Level 1 Evidence is based on ≥ 2 RCTs (randomized controlled trials) or meta-analysis.

Only Escitalopram currently has Level 1 evidence for treating or preventing depression emerging during Hepatitic C treatment.

Drug Interactions of Escitalopram with Direct-acting antiretrovirals: 

  • No interaction observed with Boceprevir.
  • 35% ↓ escitalopram AUC with Telaprevir: so may need to titrate escitalopram dose according to clinical response.

Academy members will have access to the following chapter:

This chapter will answer the following questions:

  1. Preferred Antidepressant with comorbid Hepatitis C?
  2. Drug interactions between antidepressants and Hepatitis C treatment.
  3. Which antidepressants require dosage adjustment?
  4. Which antidepressants to avoid?
  5. St. John’s Wort use with Hepatitis C?

Antidepressants use with Hepatitis C

INTERESTED IN LEARNING MORE?

JOIN PSYCHIATRY EDUCATION FORUM ACADEMY MEMBERSHIP

This is a closed membership for medical professionals only.

  • 30+ Courses/Sections: Each chapter within these sections is of direct clinical relevance for your daily practice. 
  • Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice.
  • Coffee Club: contain short discussions with clinical experts in the field of psychiatry.
  • Clinical Case Discussions: Discussions of clinical cases from our daily clinical practice. 
  • Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases.
  • Essentials of Inpatient Psychiatry Book: All chapters from this book are included in the academy sections. 
  • Goal: is to have all important clinically relevant topics in one place for ease of access.

SUBSCRIBE TO OUR EMAIL NEWSLETTER:

Related Articles